{"nctId":"NCT00696137","briefTitle":"Long-term Extension Study of BEMAâ„¢ Fentanyl","startDateStruct":{"date":"2008-06"},"conditions":["Respiratory Depression"],"count":5,"armGroups":[{"label":"BEMA Fentanyl","type":"EXPERIMENTAL","interventionNames":["Drug: BEMA Fentanyl"]}],"interventions":[{"name":"BEMA Fentanyl","otherNames":["bioerodible mucoadhesive","fentanyl buccal soluble film","ONSOLIS"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. previously qualified for and participated in study FEN-202 for at least 2 weeks,\n2. wish to continue using BEMA Fentanyl for treatment of breakthrough pain episodes, and\n3. provide signed informed consent at screening prior to any study procedures.\n\nExclusion Criteria:\n\n1. they have developed a new medical condition after initial enrollment in FEN-202 which, in the opinion of the investigator, would preclude safe and appropriate use of BEMA Fentanyl or participation in this study, or\n2. there is evidence of improper use of the study drug.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Efficacy Was Not Measured in This Study. The Number of Deaths in the Long Term Follow-up Will be Reported.","description":"Efficacy was not measured in this study as the intention was to evaluate long term safety in this population. The number of deaths in the long term follow-up will be reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":0},"commonTop":[]}}}